rs199475602
Variant summary
Our verdict is Pathogenic. Variant got 6 ACMG points: 6P and 0B. PM3PM2PP4_Moderate
This summary comes from the ClinGen Evidence Repository: The c.529G>C (p.Val177Leu) variant in PAH has been reported in multiple individuals with PAH deficiency (BH4 deficiency excluded). (PP4_Moderate). This variant has an extremely low allele frequency (Pop Max MAF=0.00005 ENF) in gnomAD (PM2). This variant was detected with pathogenic variants: F39L, L48S, F39del, R408W, R261Q, F55fs, R158Q, Trp187*. Parental testing not reported. PMID:8659548, PMID:16879198, PMID:19609714, PMID:23430918, PMID:22391997, PMID:22513348, PMID:26666653 (PM3_very-strong. Computational prediction tools and conservation analysis do not agree. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM3_very-strong, PM2. LINK:https://erepo.genome.network/evrepo/ui/classification/CA229610/MONDO:0009861/006
Frequency
Consequence
NM_000277.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PAH | NM_000277.3 | c.529G>C | p.Val177Leu | missense_variant | 6/13 | ENST00000553106.6 | NP_000268.1 | |
PAH | NM_001354304.2 | c.529G>C | p.Val177Leu | missense_variant | 7/14 | NP_001341233.1 | ||
PAH | XM_017019370.2 | c.529G>C | p.Val177Leu | missense_variant | 6/7 | XP_016874859.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PAH | ENST00000553106.6 | c.529G>C | p.Val177Leu | missense_variant | 6/13 | 1 | NM_000277.3 | ENSP00000448059 | P1 | |
PAH | ENST00000549111.5 | n.625G>C | non_coding_transcript_exon_variant | 6/6 | 1 | |||||
PAH | ENST00000307000.7 | c.514G>C | p.Val172Leu | missense_variant | 7/14 | 5 | ENSP00000303500 | |||
PAH | ENST00000551988.5 | n.550G>C | non_coding_transcript_exon_variant | 5/5 | 3 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152142Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000199 AC: 5AN: 251188Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135756
GnomAD4 exome AF: 0.00000821 AC: 12AN: 1461830Hom.: 0 Cov.: 34 AF XY: 0.00000963 AC XY: 7AN XY: 727224
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152142Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74316
ClinVar
Submissions by phenotype
Phenylketonuria Pathogenic:7
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Aug 12, 2020 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Counsyl | Oct 02, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 14, 2018 | Variant summary: PAH c.529G>C (p.Val177Leu) results in a conservative amino acid change located in the catalytic domain of the encoded protein sequence (Jeannesson-Thivisol 2015). Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.9e-05 in 276898 control chromosomes. This frequency is not higher than expected for a pathogenic variant in PAH causing Phenylalanine Hydroxylase Deficiency (Phenylketonuria) (2.9e-05 vs 0.0079), allowing no conclusion about variant significance. The variant, c.529G>C has been reported in the literature in multiple individuals affected with mild Phenylalanine Hydroxylase Deficiency (Phenylketonuria) and also found in individuals with Hyperphenylalaninemia (e.g. Djordjevic 2012, Sterl 2013, Reblova 2013, Anjema 2013, Jeannesson-Thivisol2015). These data indicate that the variant is very likely to be associated with disease. Tetrahydrobiopterin (BH4) responsiveness was reported to be inconsistent in patients, probably influenced by the other variant found in trans (Djordjevic 2012, Anjema 2013). In a recent study a compound heterozygous patient carrying this mutation with a null mutation, was found to be BH4-responsive (Jeannesson-Thivisol 2015). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Apr 30, 2023 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Molecular Diagnostics Laboratory, M Health Fairview: University of Minnesota | Oct 25, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 16, 2024 | This sequence change replaces valine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 177 of the PAH protein (p.Val177Leu). This variant is present in population databases (rs199475602, gnomAD 0.006%). This missense change has been observed in individual(s) with PAH-related conditions (PMID: 8659548, 8807331, 22513348, 23430547, 24789341, 25087612, 26666653). ClinVar contains an entry for this variant (Variation ID: 102727). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PAH protein function with a negative predictive value of 80%. This variant disrupts the p.Val177 amino acid residue in PAH. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 12501224, 17096675, 23430547, 23500595, 23764561, 27121329). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, reviewed by expert panel | curation | ClinGen PAH Variant Curation Expert Panel | Sep 22, 2019 | The c.529G>C (p.Val177Leu) variant in PAH has been reported in multiple individuals with PAH deficiency (BH4 deficiency excluded). (PP4_Moderate). This variant has an extremely low allele frequency (Pop Max MAF=0.00005 ENF) in gnomAD (PM2). This variant was detected with pathogenic variants: F39L, L48S, F39del, R408W, R261Q, F55fs, R158Q, Trp187*. Parental testing not reported. PMID: 8659548, PMID: 16879198, PMID: 19609714, PMID: 23430918, PMID: 22391997, PMID: 22513348, PMID: 26666653 (PM3_very-strong. Computational prediction tools and conservation analysis do not agree. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM3_very-strong, PM2. - |
not provided Pathogenic:2Other:1
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Oct 01, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 31, 2018 | The V177L variant in the PAH gene has been reported as a pathogenic variant in the PAH Consortium database. The V177L variant has previously been reported in association with mild phenylketonuria (PKU) and hyperphenylalaninemia (Eiken et al., 1996; Réblová et al.,2013; Jeannesson-Thivisol et al., 2015). Tetrahydrobiopterin (BH4) responsiveness is inconsistent in patients with V177L (Zurfluh et al., 2008; Sarkissian et al., 2012; Anjema et al., 2013). Therefore, we interpret V177L in PAH as a pathogenic variant. - |
not provided, no classification provided | literature only | DeBelle Laboratory for Biochemical Genetics, MUHC/MCH RESEARCH INSTITUTE | - | - - |
PAH-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Nov 10, 2022 | The PAH c.529G>C variant is predicted to result in the amino acid substitution p.Val177Leu. This patient is also heterozygous in the PAH gene for a sequence variant designated c.529G>C, which is predicted to result in the amino acid substitution p.Val177Leu. This variant has been reported, along with a second pathogenic PAH variant, in several individuals that presented with either mild hyperphenylalaninemia (MHP) or mild phenylketonuria (mPKU) (Guldberg et al. 1996. PubMed ID: 8659548; Langenbeck et al. 2009. PubMed ID: 19609714; Feillet et al. 2014. PubMed ID: 24789341; Djordjevic et al. 2013. PubMed ID: 23430547). Different substitutions of the same codon (p.Val177Met, p.Val177Ala) have also been reported in association with phenylalanine hydroxylase deficiency (Muntau et al. 2002. PubMed ID: 12501224; Jennings et al. 2000. PubMed ID: 10980574). Internally, we have observed the c.529G>C (p.Val177Leu) variant along with a second pathogenic PAH variant in affected individuals. This variant is also documented in the PAH variant database (http://www.biopku.org/home/home.asp) and is classified as a MHP variant. Additionally, it is interpreted as pathogenic by the ClinGen PAH Variant Curation Expert Panel and as pathogenic or likely pathogenic by other outside laboratories (https://www.ncbi.nlm.nih.gov/clinvar/variation/102727/). Based on the collective evidence, this variant is interpreted as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at